Sofpironium Bromide Gel, 15%
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Axillary Hyperhidrosis
Conditions
Primary Axillary Hyperhidrosis
Trial Timeline
Dec 21, 2018 → Sep 6, 2019
NCT ID
NCT03785587About Sofpironium Bromide Gel, 15%
Sofpironium Bromide Gel, 15% is a phase 2 stage product being developed by Botanix Pharmaceuticals for Primary Axillary Hyperhidrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03785587. Target conditions include Primary Axillary Hyperhidrosis.
What happened to similar drugs?
20 of 20 similar drugs in Primary Axillary Hyperhidrosis were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03836287 | Phase 3 | Completed |
| NCT03785587 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Axillary Hyperhidrosis